1.965

2.72% -0.055

Alx Oncology Holdings Inc (ALXO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$2.02

Offen:

$2.04

24-Stunden-Volumen:

308.60K

Relative Volume:

0.58

Marktkapitalisierung:

$257.80M

Einnahmen:

Nettoeinkommen (Verlust:

$-101.70M

KGV:

-1.0363

EPS:

-1.8961

Netto-Cashflow:

$-84.35M

1W Leistung:

-11.09%

1M Leistung:

-11.09%

6M Leistung:

+85.38%

1J Leistung:

+136.35%

1-Tages-Spanne:

$1.965

$2.04

1-Wochen-Bereich:

$1.965

$2.30

52-Wochen-Spanne:

$0.404

$2.66

Alx Oncology Holdings Inc Stock (ALXO) Company Profile

Firmenname

Alx Oncology Holdings Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

650-466-7125

Adresse

323 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

ALXO's Discussions on Twitter

Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALXO Alx Oncology Holdings Inc	1.965	265.02M	0	-101.70M	-84.35M	-1.8961
VRTX Vertex Pharmaceuticals Inc	470.36	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.68	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	702.39	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.56	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.18	31.65B	5.36B	287.73M	924.18M	2.5229

Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-06	Fortgesetzt	UBS	Buy
2025-11-13	Eingeleitet	Jefferies	Buy
2025-03-06	Hochstufung	Jefferies	Hold → Buy
2024-12-19	Herabstufung	Jefferies	Buy → Hold
2024-03-08	Herabstufung	Stifel	Buy → Hold
2023-12-08	Hochstufung	Jefferies	Hold → Buy
2021-12-22	Herabstufung	Jefferies	Buy → Hold
2021-09-30	Eingeleitet	Stifel	Buy
2021-05-05	Fortgesetzt	Credit Suisse	Outperform
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-04-06	Eingeleitet	UBS	Buy
2021-02-10	Eingeleitet	H.C. Wainwright	Buy
2020-08-11	Eingeleitet	Cantor Fitzgerald	Overweight
2020-08-11	Eingeleitet	Credit Suisse	Outperform
2020-08-11	Eingeleitet	Jefferies	Buy
2020-08-11	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten

11:24 AM

Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView

11:24 AM

09:34 AM

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - The Globe and Mail

09:34 AM

Mar 12, 2026

RLMD Stock Surges 42% in a Week: Here's What You Should Know - TradingView

Mar 12, 2026

Mar 11, 2026

Alx Oncology Faces Renewed Nasdaq Listing Risk After Prior Minimum Bid Price Violation - TipRanks

Mar 11, 2026

Mar 10, 2026

GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz

Mar 10, 2026

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - TradingView

Mar 10, 2026

ALX Oncology 2025 Annual Report: Evorpacept Clinical Trials, Pipeline Strategy, and CD47 Blockade Advancements - Minichart

Mar 10, 2026

ALX Oncology's (ALXO) Buy Rating Reiterated at HC Wainwright - MarketBeat

Mar 10, 2026

ALXO: HC Wainwright Reiterates Buy Rating with Price Target at $4.00 | ALXO Stock News - GuruFocus

Mar 10, 2026

Mar 09, 2026

ALX 2025 10-K: Net loss $101.7M, EPS $(1.90); operating loss $(104.0)M - TradingView

Mar 09, 2026

Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study - Finviz

Mar 09, 2026

Mar 08, 2026

Aug Momentum: What is ALX Oncology Holdings Incs book value per share2026 AllTime Highs & Low Risk High Win Rate Picks - baoquankhu1.vn

Mar 08, 2026

Mar 07, 2026

Alx Oncology Earnings Call Highlights Biomarker Momentum - TipRanks

Mar 07, 2026

ALX Oncology initiated with a Buy at UBS - Yahoo Finance

Mar 07, 2026

Mar 06, 2026

Aug Retail: Does ALX Oncology Holdings Inc stock have upside surprise potentialWatch List & Consistent Income Trade Ideas - baoquankhu1.vn

Mar 06, 2026

ALX Oncology (NASDAQ:ALXO) Coverage Initiated by Analysts at UBS Group - MarketBeat

Mar 06, 2026

ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) - The Globe and Mail

Mar 05, 2026

Mar 04, 2026

ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - The Globe and Mail

Mar 04, 2026

Mar 03, 2026

ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update - MarketBeat

Mar 03, 2026

Pharma News: Can Piedmont Office Realty Trust Inc grow without external fundingStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn

Mar 03, 2026

Mar 02, 2026

ALX Oncology Q4 Earnings Call Highlights - Defense World

Mar 02, 2026

ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - marketscreener.com

Mar 02, 2026

Mar 01, 2026

ALXO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 01, 2026

ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO) - Seeking Alpha

Mar 01, 2026

Feb 28, 2026

Earnings Scheduled For February 27, 2026 - Sahm

Feb 28, 2026

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 28, 2026

Feb 27, 2026

ALXO's Progress in Clinical Trials and Financial Strength - GuruFocus

Feb 27, 2026

ALX Oncology (NASDAQ:ALXO) Posts Earnings Results - MarketBeat

Feb 27, 2026